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Abstract
Inhalational general anesthesia results from the poorly understood interactions of
haloethers with multiple protein targets, which prominently includes ion channels in the
nervous system. Previously, we reported that the commonly used inhaled anesthetic sevo-
flurane potentiates the activity of voltage-gated K+ (Kv) channels, specifically, several
mammalian Kv1 channels and the Drosophila K-Shaw2 channel. Also, previous work sug-
gested that the S4-S5 linker of K-Shaw2 plays a role in the inhibition of this Kv channel by
n-alcohols and inhaled anesthetics. Here, we hypothesized that the S4-S5 linker is also a
determinant of the potentiation of Kv1.2 and K-Shaw2 by sevoflurane. Following functional
expression of these Kv channels in Xenopus oocytes, we found that converse mutations in
Kv1.2 (G329T) and K-Shaw2 (T330G) dramatically enhance and inhibit the potentiation of
the corresponding conductances by sevoflurane, respectively. Additionally, Kv1.2-G329T
impairs voltage-dependent gating, which suggests that Kv1.2 modulation by sevoflurane is
tied to gating in a state-dependent manner. Toward creating a minimal Kv1.2 structural
model displaying the putative sevoflurane binding sites, we also found that the positive
modulations of Kv1.2 and Kv1.2-G329T by sevoflurane and other general anesthetics are
T1-independent. In contrast, the positive sevoflurane modulation of K-Shaw2 is T1-depen-
dent. In silico docking and molecular dynamics-based free-energy calculations suggest
that sevoflurane occupies distinct sites near the S4-S5 linker, the pore domain and around
the external selectivity filter. We conclude that the positive allosteric modulation of the Kv
channels by sevoflurane involves separable processes and multiple sites within regions
intimately involved in channel gating.
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Introduction
Every year, millions of patients around the world undergo general anesthesia to perform
major surgeries. However, the mechanisms of general anesthesia, which involve multiple
targets, are poorly understood. Also, although general anesthesia is considered generally
safe, the drugs currently used lack specificity and have narrow therapeutic indices. Thus, it is
necessary to understand anesthesia at all levels to help develop specific, effective and less
toxic general anesthetics. Diverse ion channels in the nervous system are likely to be major
targets of general anesthetics [1]. Among them, neurotransmitter-gated ion channels and
non-gated K+ channels have received most of the attention [1, 2]; however, recent work con-
tinues to suggest that voltage-gated ion channels are also important players in general anes-
thesia [3–7].
In particular, recent discoveries have reassessed the likely role of certain Kv1 channels in
general anesthesia [7–9]. Kv1.2 channels encoded by Kcna2 gene are widely expressed in the
brain and mainly localize in the axon initial segment, the juxtaparanodal region of myelin-
ated axons and axon terminals [10–12]. In these locations, heteromultimeric Kv channels
including Kv1.1 and Kv1.2 subunits help regulate action potential threshold, repolarization,
propagation and firing patterns [12]. Kcna2-null mice exhibit a severe brainstem seizure phe-
notype, which is often lethal [12]. The findings of Alkire et al. [8] and Lioudyno et al. [9] are
especially significant. Whereas the first study found that infusion of an anti-Kv1.2 antibody
into the CMT of the rat reverses anesthesia, the second reported a similar result upon infu-
sion of a specific neurotoxin to block Kv1.1, Kv1.3 and Kv1.6 channels. Moreover, tonic firing
of action potentials in neurons of the CMT is inhibited by sevoflurane, which lengthens the
interspike interval, and this inhibition is prevented by the aforementioned Kv1-specific
neurotoxin.
Sevoflurane is commonly used in human general anesthesia and is a unique positive mod-
ulator of several Kv1 channels and the Drosophila K-Shaw2 channel in heterologous expres-
sion systems [7, 9]. At relevant concentrations, it induces a negative shift in the conductance-
voltage relation and increases the maximum conductance. By contrast, most other common
general anesthetics either interact weakly or inhibit Kv channels (namely, K-Shaw2). Since
K+ channel activity opposes excitation, the unique potentiation of Kv channels by sevoflurane
could contribute to anesthesia. Here, we investigated the structural basis of this positive mod-
ulation in the mammalian Kv1.2 channel. Previous work strongly implicated the S4-S5 linker
as a determinant of the inhibition of K-Shaw2 by general anesthetics [6, 13]. The S4-S5 linker
connects the voltage-sensing domain to the pore domain of the Kv channels and is responsi-
ble for the electromechanical coupling that controls voltage-dependent gating [14, 15]. In
this study, we investigated the contributions of the S4-S5 linker to the positive modulation of
the Kv1.2 and K-Shaw2 channels by sevoflurane. The results revealed that discrete structural
changes in this linker drastically affect the response of these Kv channels to the anesthetic by
altering electromechanical coupling. Other results strongly suggest additional novel sites,
which are necessary to fully explain the modulation of Kv channels by sevoflurane. Support-
ing a multisite model of general anesthetic action, molecular dynamics, docking simulations
and free energy estimations demonstrate two significant classes of sevoflurane binding sites.
One set in the pore domain (including the C-terminal side of the S4-S5 linker) and another
near the external selectivity filter of the Kv1.2 channel. We propose that positive multisite
allosteric modulation of Kv channel gating by sevoflurane plays a significant role in general
anesthesia.
Potentiation Mechanism of Kv1.2 by Sevoflurane
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Materials and Methods
Molecular biology and heterologous expression
Plasmid maintenance, mutagenesis, sequence, RNA synthesis and oocyte microinjection were
carried out as previously described [6, 7].
Ethics Statement
Xenopus laevis surgeries were performed according to a protocol approved by the Thomas Jef-
ferson University IACUC.
Electrophysiology
Whole-oocyte currents were recorded at room temperature (21–23°C) under two-electrode
voltage-clamp conditions (OC-725C, Warner Instrument, Hamden, CT) according to estab-
lished procedures [6, 7]. Data acquisition, leak subtraction and initial analysis were performed
using pClamp 9.2 and 10.3 (Molecular Devices, Sunnyvale, CA). The pipette was filled with 3
M KCl. The extracellular solution was ND96 (in mM): 96 NaCl, 2 KCl, 1.8 CaCl2, 1 MgCl2, 5
HEPES, 2.5 sodium pyruvate, adjusted to pH 7.4 with NaOH. ND96 and n-butanol were deliv-
ered using a gravity-driven perfusion system. Volatile anesthetics were delivered manually
using a Hamilton gastight syringe (Hamilton, Reno, NV). The preparation and dilution of all
drugs were done as previously described [6, 7].
Data analysis
Data analysis, plotting and curve-fitting were performed in Origin 9.1 (OriginLab, Northamp-
ton, MA).
G-V relations. Peak chord conductance (G = I/[Vc−Vr]) was determined assuming -95 mV
as the reversal potentials (Vr). I is the peak current and Vc is the command voltage. G-V rela-
tions were then described by assuming this form of the Boltzmann equation:
G ¼ Gmax
1þ e
ðVc  V1=2Þ
k
or the double Boltzmann equation:
G ¼ Gmax1
1þ e
VcV1=2;1
k1
þ Gmax2
1þ e
VcV1=2;2
k2
where Gmax is the maximum conductance; V1/2 is the voltage at which the conductance is at
50% of its maximal amplitude; and k is the slope factor. The following equation was used to
calculate the equivalent gating charge: z = RT/Fk = 25.5/k, where R, T and F are the gas con-
stant, absolute temperature and Faraday constant, respectively. The Vmed was also determined
to evaluate multiphasic G-V relations in a curve ﬁtting-independent manner. Vmed is the volt-
age at which the total conductance (Gmax1 + Gmax2) is at its midpoint (median). This determi-
nation allowed semiquantitative assessment of multiphasic G-V relation shifts without the
ambiguity typically associated with curve-ﬁtting involving a large number of correlated
adjustable parameters.
All G-V data were obtained from paired sets (same oocyte in the absence and presence of
sevoflurane). Measurement of the control G-V relation was followed by determination of a sta-
ble response to sevoflurane (current evoked by a depolarizing step to +60 mV, before and after
Potentiation Mechanism of Kv1.2 by Sevoflurane
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exposure to sevoflurane) and subsequent measurement of the experimental G-V relation. All
parameters extracted from the analysis of these relations were compared in a pairwise manner.
To display the results from different oocytes and estimate the magnitude of relative changes
(before and after exposure to sevoflurane), individual G-V relations were normalized to the
control Gmax before exposure to sevoflurane (G/Gmax). Accordingly, a relative G/Gmax = 1,<1
and>1 indicates no change, inhibition and potentiation, respectively (Table A in S1 File). Con-
ductance ratio (GSevo/G0, conductance in the presence of sevoflurane over control conduc-
tance) vs. voltage plots were additionally generated to directly visualize the G-V relation
change (e.g., Fig 1C). All results were reported as mean ± SEM, and the paired Student t-test
was used to evaluate the statistical significance of apparent differences, unless stated otherwise.
Concentration-response relations. Normalized dose-inhibition relations were described by
assuming this form of the Hill equation:
I
I0
¼ A1 þ
xnH
KnH þ xnH
or a double Hill equation:
I
I0
¼ 1þ 1þ A1
1þ K1
x
 nH1 þ
1þ A2
1þ K2
x
 nH2
where, I/I0 is the normalized current and x is the drug concentration, K (apparent dissociation
equilibrium constant) is the drug concentration that induces 50% inhibition/potentiation, and
nH is the index of cooperativity or Hill coefﬁcient (Table 1). We do not report SEM for the esti-
mated best-ﬁt Hill equation parameters because complete concentration-response relations
and the corresponding best-ﬁt function cannot be constructed from an individual oocyte.
Although the action of all anesthetics tested is generally reversible [7], it is often difﬁcult to
obtain complete washout of inhaled anesthetics when testing multiple concentrations on the
same oocyte. This complication would produce a cumulative effect, which distorts the concen-
tration-response relation. To avoid this problem, each data point on the concentration-
response relation represents the mean ± SEM from several independent determinations on dif-
ferent oocytes at the indicated concentrations. For each anesthetic, therefore, there is only one
best-ﬁt estimate that collectively describes the combined results from several oocytes individu-
ally tested at different concentrations. This approach has produced reproducible results as
reported previously [6, 7].
Computational Methods
Kv1.2 models in the closed/resting and open/activated states were obtained from Delemotte
et al. [16] and Treptow & Tarek [17]. Each model was previously acquired via molecular
dynamics (MD) simulations of the published x-ray crystal structure [18]. Details and validation
of the models are as reported in the original papers mentioned above. Structural models of the
Kv1.2-G329T mutant were built on the basis of the mentioned Kv1.2 constructs using the
psfgen package implemented in VMD [19]. After insertion in a lipid bilayer, each of the
structures was equilibrated by MD runs using the program NAMD 2.9 [20] and applying
CHARMM 36 force field [21]. Specifically, sevoflurane molecules were then docked against the
generated ensemble of membrane-equilibrated channel structures in order to explore putative
binding sites using AutoDock Vina [22]. The Linear Interaction Energy (LIE) method [23] was
adopted for calculation of the binding free energies and, thus, the corresponding binding con-
stants. Assuming that the predicted binding sites act independently, these binding constants
Potentiation Mechanism of Kv1.2 by Sevoflurane
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were computed for individual sites in different functional conformations. Additional details
are provided under S1 File.
Results
Screening the effects of general anesthetics on the Kv1.2 current
Previous studies showed that several heterologously expressed Kv1 channels are potentiated by
anesthetic concentrations of sevoflurane [7, 9]. This modulation results primarily from shifting
the G-V relation to the left and increasing the Gmax (e.g., Kv1.2; Fig 1). Sevoflurane shifts the
Kv1.2 V1/2 by -4 mV and increases the Gmax by 13% (Figs 1A, 1B and 2A; Table A in S1 File). A
close examination of the Kv1.2 GSevo/G0 –voltage relation also shows a substantial sevoflurane-
induced potentiation of the conductance at -30 mV (~180%) and a sustained potentiation at
positive membrane potentials, which corresponds to the increase in Gmax (Fig 1C). The poten-
tiation at -30 mV is particularly significant because it is within the range where sevoflurane
could affect action potential firing.
To additionally screen isoflurane, halothane, chloroform, propofol and n-butanol, we tested
their effects on the Kv1.2 current at +60 mV (Fig 3). Sevoflurane and isoflurane (1 mM) mod-
estly potentiate the Kv1.2 conductance by 12.4 ± 1.7% and 11.5 ± 3.1%, respectively (Fig 3B).
For sevoflurane, K and nH are 360 μM and 3.3, respectively, which demonstrates relevant
Fig 1. Positive modulation of the Kv1.2 conductance by sevoflurane. (A) Families of whole-oocyte Kv1.2 currents before (left) and after exposure to 1
mM sevoflurane (center). Currents were evoked by step depolarizations from a holding voltage of -100 mV. The steps were delivered in increments of 10 mV
from -50 to +50 mV. The overlay (right) directly compares selected currents in the absence (black) and presence (red) of sevoflurane (currents evoked by
steps to the indicated voltages). (B) NormalizedG-V relations of Kv1.2 in the absence (black) and presence of 1 mM sevoflurane (red) (N = 6). The solid lines
are the best-fit Boltzmann functions.Gmax is the control maximum conductance before exposure to sevoflurane (Materials and Methods). The mean best-fit
parameters are summarized in Table A in S1 File. (C) The voltage dependence of the Kv1.2 conductance ratio (GSevo/G0). This ratio was calculated from
paired measurements of theG-V relations before (G0) and after exposure to sevolfurane (GSevo).
doi:10.1371/journal.pone.0143363.g001
Potentiation Mechanism of Kv1.2 by Sevoflurane
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pharmacological potency and apparent cooperativity (Fig 3B and Table 1). Potentiation by iso-
flurane was already maximal at 100 μM and apparent binding parameters were not estimated.
By contrast to sevoflurane and isoflurane, halothane, chloroform and propofol displayed only
modest inhibitory effects, while high concentrations of n-butanol produced a more robust inhi-
bition (Fig 3B). Focusing on sevoflurane, we noticed that the previously reported potentiation
of K-Shaw2 at +60 mV is ~3-fold greater than that of Kv1.2 [7]. Based on earlier work [6], we
hypothesized that differences in the linker connecting the voltage-sensing domain to the pore
domain (S4-S5 linker) might explain the differential responses to sevoflurane.
A single amino acid substitution in the Kv1.2 S4-S5 linker (G329T)
confers dramatic potentiation by general anesthetics
To investigate the role of the S4-S5 linker in the modulation of Kv1.2 by general anesthetics, we
focused on fourteen residues between positions 317 and 330 in K-Shaw2. Within the equivalent
region in Kv1.2, there are six substitutions (Fig 4A). The Kv1.2-G319I mutation is, however,
lethal (not shown). Therefore, to test the impact of the remaining differences, we converted
the S4-S5 linker of Kv1.2 into that of K-Shaw2 between the corresponding Kv1.2 positions
Table 1. Concentration-response parameters of the modulation of selected Kv channels by sevoflurane and other general anesthetics.
K1 (mM) nH1 A1 K2 (mM) nH2 A2
Kv1.2
Sevofurane 0.36 3.3 1.13
n-butanol 78.4 1.3
Kv1.2 FRAKT
Sevofurane 0.33 2.0 1 1.45 4.0 2.50
Isoﬂurane 0.23 2.2 1 0.47 9.4 1.24
Halothane 0.16 1.6 1 0.63 7.9 1.24
Propofol 0.02 2.2 2.89
n-butanol 100.5 1.5
ΔT1-Kv1.2 FRAKT
Sevofurane 0.32 2.9 1 1.84 3.8 3.17
Isoﬂurane 0.22 1.2 1 0.40 3.4 1.96
Halothane 0.23 1.0 1 0.77 3.4 0.93
Propofol 0.02 1.7 2.66
n-butanol 91.9 1.6
Kv1.2 G329T
Sevofurane 0.40 1.6 1 2.2 2.8 2.20
K-Shaw2*
Sevofurane 0.06 1 0.59 4 1 1.23
Isoﬂurane 1.69 2.1
Halothane 0.26 1.3
Chloroform 0.70 1.4
Propofol 0.06 1.6
n-butanol 10.1 1.8
ΔT1-K-Shaw2
Halothane 0.38 1.4
n-butanol 16.4 1.5
* Sevoﬂurane tested at -20 mV, from Barber et al. [7].
doi:10.1371/journal.pone.0143363.t001
Potentiation Mechanism of Kv1.2 by Sevoflurane
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Fig 2. Analysis ofG-V relations from Kv1.2,ΔT1-Kv1.2, K-Shaw2, K-Shaw2 T330G and ΔT1-K-Shaw2.
(A) Best-fit Boltzmann parameters (V1/2, z andGmax) from individual paired measurements before (Ctr) and
after exposure to 1 mM sevoflurane (Sevo). Each pair of symbols connected by a solid line represents an
individual paired experiment (Materials and Methods). TheGmax graphs depict raw values before
normalization (in mS). The P value resulting from a paired Student-t test is shown above each graph, and the
redmarks indicate the mean values of the sample. (B)–(E) are as described for panel A. The number oocytes
examined for each Kv channel was 6, 6, 4, 6 and 6, respectively.
doi:10.1371/journal.pone.0143363.g002
Potentiation Mechanism of Kv1.2 by Sevoflurane
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(residues 319–329) to create the Kv1.2-FRAKT chimera. Kv1.2-FRAKT currents evoked by a
depolarizing step to +60 mV exhibit a dramatically different pattern of responses to various
general anesthetics (Fig 4B and 4C). Sevoflurane, isoflurane, halothane, chloroform and propo-
fol all potentiate the conductance to various degrees, while the inhibitory response to n-butanol
remained unaffected. Also, the concentration-potentiation relations for sevoflurane, isoflurane
and halothane exhibit complex profiles, which are reminiscent of the previously described
potentiation of the K-Shaw2 channel by sevoflurane [7]. The concentration dependence of the
potentiation is a biphasic phenomenon, occurring gradually at low concentrations and sharply
at higher concentrations (Fig 4C). To empirically characterize this behavior, we assumed two
classes of independent binding sites exhibiting (Materials and Methods; Fig 4C): 1) apparent
high affinity and no cooperativity (nH 1); and 2) apparent low affinity and highly cooperative
Fig 3. Modulation of the Kv1.2 channel by general anesthetics. (A) Effects of general anesthetics on the
whole-oocyte Kv1.2 currents evoked by a voltage step to +60 mV from a holding voltage of -100 mV. Black,
red and grey current traces correspond to control, anesthetic-exposed, and washout, respectively. The scale
bars indicate 50 ms and 0.5 μA. (B) Concentration-response relations of various general anesthetics acting
on the Kv1.2 channel. Solid lines are the best fits assuming the Hill equation for sevoflurane and n-butanol
(Materials and Methods). Considering the magnitude of the change and the concentrations tested, only
sevoflurane and n-butanol produced reliable Hill equation fits. N = 5–7 oocytes for each concentration. Best-
fit parameters are summarized in Table 1.
doi:10.1371/journal.pone.0143363.g003
Potentiation Mechanism of Kv1.2 by Sevoflurane
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interactions (nH>>1). Although propofol is the most potent, sevoflurane exhibits the highest
efficacy followed by isoflurane, halothane and chloroform (Fig 4C and Table 1). Maximum
potentiation by propofol, isoflurane and halothane is, however, similar (2.7 to 3.3-fold above
control; Table 1). Although the S4-S5 mutations conferred enhanced potentiation of Kv1.2 by
sevoflurane that is similar to that previously observed with K-Shaw2, they also introduced
novel potentiation by other general anesthetics. Thus, discrete structural changes in the S4-S5
Fig 4. Modulation of Kv1.2 FRAKT by general anesthetics. (A) Sequence alignment of the S4-S5 linker
from K-Shaw2 (314–332) and Kv1.2 (313–331) channels. Starting and ending residue numbers of the shown
segments are indicated. In Kv1.2, the blue colored residues were swapped for the red colored residues in
K-Shaw2 to create the Kv1.2 FRAKTmutant channel. (B) Effects of general anesthetics on whole-oocyte
Kv1.2-FRAKT currents evoked by a voltage step to +60 mV from a holding voltage of -100 mV. Black, red and
grey current traces correspond to control, anesthetic-exposed, and washout, respectively. The scale bars
indicate 50 ms and 0.5 μA. (C) Concentration-response relations of various general anesthetics acting on the
Kv1.2 FRAKT channel. Solid lines are the best fits assuming the Hill equation (propofol and n-butanol) or a
double Hill equation (sevoflurane, isoflurane, and halothane) (Materials and Methods). Due to the small
magnitude of the chloroform results, no reliable Hill equation fit could be obtained. N = 5–8 oocytes for each
concentration. Best-fit parameters are summarized in Table 1.
doi:10.1371/journal.pone.0143363.g004
Potentiation Mechanism of Kv1.2 by Sevoflurane
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linker can dramatically influence the ways in which general anesthetics interact with Kv chan-
nels. Since sevoflurane is clinically relevant and is the most efficacious positive modulator on
Kv1.2-FRAKT and K-Shaw2, we focused on this anesthetic to dissect the structural basis of the
potentiation.
To determine the specific amino acid(s) responsible for the dramatic sevoflurane potentia-
tion of Kv1.2-FRAKT, we tested each substitution individually by creating the following Kv1.2
mutants: L321F, K322R, M325A, R326K and G329T. Whereas the potentiation of L321F,
K322R, M325A, R326K is similar to that of wild type Kv1.2, G329T exhibited dramatic potenti-
ation not significantly different from that of Kv1.2-FRAKT (two-way ANOVA, P>0.05; Fig 5
and Table 1). These results suggest that a single residue in the S4-S5 linker is a critical determi-
nant of the potentiation of the Kv1.2 current by sevoflurane.
Kv1.2-FRAKT and Kv1.2-G329T exhibit novel voltage dependent gating
The G329T mutation could have affected voltage-dependent gating and thereby allosterically
(depending on conformation) influence the interaction of sevoflurane with the channel.
Although the mutations do not appear to have gross effects on the overall current kinetics,
Kv1.2–FRAKT and G329T dramatically remodel the G-V relation (Materials and Methods).
Within a narrow range of membrane potentials (10–20 mV), the wild type Kv1.2 G-V relation
sharply rises to the maximum conductance (Gmax) between +20 and +40 mV (Fig 1B). By con-
trast, the G-V relations of Kv1.2-FRAKT and Kv1.2-G329T rise to the Gmax in a more gradual
manner and exhibit two distinct components (Fig 6A). These G-V relations approach Gmax at
voltages> +100 mV and require the sum of at least two Boltzmann terms to adequately
describe them (Fig 6B). Moreover, the G-V relations of Kv1.2-FRAKT and Kv1.2-G329T have
similar profiles, albeit there are some quantitative differences (Fig 6; Table A in S1 File). For
Kv1.2-FRAKT and Kv1.2-G329T: the median voltages (Vmed) are 22±2 and 28±2 mV, respec-
tively (Fig 6). Relative to Kv1.2-FRAKT, Kv1.2-G329T modestly depolarizes V1/2,1 by ~13 mV
and induces a 16 mV negative shift of V1/2,2 (Fig 6; Table A in S1 File). The corresponding
equivalent gating charges (z1 and z2) increase from 2.7±0.1 to 4.8±0.1 e0, and from 0.9±0.1 to
1.5±0.1 e0 (Fig 6; Table A in S1 File). Nevertheless, among all individual FRAKT mutations,
G329T is the only one that closely recapitulates the behavior of the Kv1.2-FRAKT indicating
that it plays the most critical role in determining the novel gating phenotype of the chimera.
Individual mutations of other residues (L321F, K322R, M325A, R326K) had little to no effect
on Kv1.2 G-V relation (Fig A in S1 File).
Upon exposure to 1 mM sevoflurane, the G-V relations of Kv1.2-FRAKT and Kv1.2-G329T
display changes that are qualitatively similar to those observed with Kv1.2 wild type; however,
the net magnitudes are substantially larger (Fig 7A and 7B; Table A in S1 File). ΔVmed shifts to
the left by ~15 and ~20 mV, respectively. On Kv1.2-FRAKT, sevoflurane induced small-modest
changes in V1/2,1, z1 and z2; however, sevoflurane most noticeably doubles the total conduc-
tance (GTOTAL = Gmax1+Gmax2 = 2.07) as a result of increasing Gmax1 (0.37 to 0.99) and Gmax2
(0.63 to 1.07) (Fig 7A; Table A in S1 File). Kv1.2-G329T, in contrast, displayed more selective
effects on the bimodal G-V relation. The V1/2,1 and z1 are not affected, whereas the sevoflur-
ane-induced negative ΔV1/2,2 is substantial (-11 mV, with no change in z2). Additionally, as
found with Kv1.2-FRAKT, sevoflurane nearly doubles the total Kv1.2-G329T conductance
(GTOTAL = 1.89) (Fig 7B; Table A in S1 File). These results demonstrate that G329T alone
markedly alters gating and concomitantly enhances the potentiation by sevoflurane, suggesting
a strong link between voltage-dependent gating and anesthetic action.
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K-Shaw2-T330G eliminates the sevoflurane-induced voltage-dependent
shift without affecting the sevoflurane-induced increase inGmax
Since G329 in Kv1.2 critically controls voltage-dependent activation and keeps positive modu-
lation by sevoflurane in check, we asked whether the reverse mutation in K-Shaw2 (T330G)
would inhibit the naturally robust potentiation of this Kv channel by sevoflurane. In contrast
to Kv1.2-G329T, K-Shaw2-T330G does not significantly affect the G-V relation (Fig 2; Table A
in S1 File); however, it abolishes the sevoflurane-induced leftward shift of the G-V relation
(Figs 2, 8A and 8B; Table 1; Table A in S1 File). Accordingly, T330G dramatically inhibits the
potentiated conductance ratio (GSevo/G0) from ~10 to ~1.3 at -40 mV (Fig 8C). However, the
sevoflurane-induced increase in the Gmax of K-Shaw2-T330G and wild type K-Shaw2 are very
similar (1.4- and 1.6-fold, respectively; Table A in S1 File). Accordingly, the GSevo/G0 of wild
type and mutant channels converge toward a similar value at +100 mV (~1.5; Fig 8C). This
Fig 5. Kv1.2 G329T recapitulates the magnified positive modulation of Kv1.2 FRAKT by sevoflurane.
(A) Effects of 1 mM sevoflurane on mutant whole-oocyte Kv1.2 currents evoked by a voltage step to +60 mV
from a holding voltage of -100 mV. Black, red and grey current traces correspond to control, anesthetic-
exposed, and washout, respectively. The scale bars indicate 50 ms and 1 μA. (B) Concentration-response
relations of various general anesthetics acting on wild type and mutant Kv1.2 currents. Solid lines are the
best fits assuming the double Hill equation (Materials and Methods). N = 4–8 oocytes for each dose. Best-fit
parameters are summarized in Table 1.
doi:10.1371/journal.pone.0143363.g005
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result suggests that the positive modulation induced by sevoflurane has two separable compo-
nents. One depends on the role of a specific residue in the S4-S5 linker that controls voltage-
dependent gating, whereas the other is independent of that residue and namely affects the
Gmax.
The role of the T1 domain on the modulations of Kv1.2, Kv1.2-FRAKT
and K-Shaw2 by sevoflurane
Previous studies strongly suggest that the intracellular regulatory T1 domain of Kv channels
plays a significant role in gating [24–28]. Thus, we asked whether the T1 domain might also
contribute to the positive modulation of Kv1.2, Kv1.2-FRAKT and K-Shaw2, by sevoflurane.
In ΔT1-Kv1.2 and ΔT1-Kv1.2-FRAKT, residues 2–122 are missing; and ΔT1-K-Shaw2 lacks
residues 2–155. ΔT1-Kv1.2 and ΔT1-Kv1.2-FRAKT exhibited G-V relations and responses to
general anesthetics that are similar to those from their full-length counterparts (Figs 2B, 7C,
9A and 9B; Fig B and Table A in S1 File). Sevoflurane shifted the ΔT1-Kv1.2 V1/2 by -4 mV,
and increased the Gmax by 10%. It also shifted the ΔT1-Kv1.2-FRAKT Vmed by -19 mV and
nearly doubled the GTOTAL (1.9-fold). By contrast, ΔT1-K-Shaw2 exhibited a substantially left-
ward shifted G-V relation (-48 mV; data not shown) and no positive effect of sevoflurane on
V1/2 and Gmax (Fig 2; Table A in S1 File). These results suggest that voltage-dependent gating
of Kv1.2 and Kv1.2-FRAKT and their modulation by general anesthetics are independent of
the T1 domain. K-Shaw2 gating and its positive modulation by sevoflurane are, however,
completely dependent on the presence of the T1 domain, suggesting specialized interactions
between the T1 domain and the gating apparatus of the K-Shaw2 channel. Thus, we can infer
that the dual positive modulation of the Kv1.2 channel by sevoflurane (leftward shifted G-V
relation and increased Gmax) only implicates regions directly involved in gating (the voltage-
sensing and pore domains). Based on this outcome, we created minimal atomic models of
Fig 6. NovelG-V relations of Kv1.2 FRAKT and Kv1.2 G329T in the absence and presence of sevoflurane. (A) Families of whole-oocyte Kv1.2 FRAKT
currents in the absence (left) and presence of 1 mM sevoflurane (right). Currents were evoked by step depolarizations from a holding voltage of -100 mV. The
steps were delivered in increments of 10 mV from -90 to 130 mV. The scale bars indicate 100 ms and 2 μA. (B) Families of whole-oocyte Kv1.2 G329T
currents in the absence (left) and presence of 1 mM sevoflurane (right). Currents were evoked by step depolarizations from a holding voltage of -100 mV. The
steps were delivered in increments of 10 mV from -90 to 70 mV. The scale bars indicate 100 ms and 1 μA. (C)G-V relations of Kv1.2 FRAKT (red) and Kv1.2
G329T (blue) under control (open) or with 1 mM Sevoflurane (filled) (N = 6, 4, respectively). Solid lines are the best fits assuming a double Boltzmann
equation (Materials and Methods). The best-fit parameters are summarized in Table A in S1 File.
doi:10.1371/journal.pone.0143363.g006
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Fig 7. Analysis of bimodalG-V relations from Kv1.2 FRAKT, Kv1.2 G329T andΔT1-Kv1.2 FRAKT. (A)
Best-fit double Boltzmann parameters (V1/2,1, z1,Gmax,1, V1/2,2, z2,Gmax,2) and Vmed from individual paired
measurements before (Ctr) and after exposure to 1 mM sevoflurane (Sevo). Each pair of symbols connected
by a solid line represents an individual paired experiment (Materials and Methods). TheGmax graphs depict
raw values before normalization (in mS). The P value resulting from a paired Student-t test is shown above
each graph, and the redmarks indicate the mean values of the sample. (B)–(C) are as described for panel A.
The number oocytes examined for each Kv channel was 6, 4, 5, respectively.
doi:10.1371/journal.pone.0143363.g007
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ΔT1-Kv1.2 and ΔT1-Kv1.2 G329T to explore putative in-silico interaction sites in the trans-
membrane regions of the channel.
Putative sevoflurane binding sites in ΔT1-Kv1.2 and ΔT1-Kv1.2-G329T
The results so far demonstrate that 1) sevoflurane potentiates the Kv1.2 current with relevant
apparent affinity and cooperativity and is independent of the T1 domain; 2) sevoflurane inter-
acts with two independent classes of sites in K-Shaw2, Kv1.2-FRAKT and Kv1.2-G329T (with
apparent high and low affinities); 2) G329T is sufficient to confer dramatic positive modulation
by sevoflurane and other general anesthetics; 3) the potentiation of Kv1.2-G329T by sevoflur-
ane resembles the action of this anesthetic on K-Shaw2; 4) G329T fully recapitulates the
electrophysiological and pharmacological phenotype of the Kv1.2-FRAKT chimera, which is
Fig 8. The T330Gmutation eliminates the voltage-dependent potentiation of the K-Shaw2 conductance by sevoflurane. (A) Families of whole-oocyte
K-Shaw2 (N = 4) and K-Shaw2 T330G (N = 6) currents in the absence (left) and presence of 1 mM sevoflurane (right). Currents were evoked by step
depolarizations from a holding voltage of -100 mV. The steps were delivered in increments of 10 mV from -90 to +100 mV. The scale bars indicate 100 ms
and 1 μA. (B)G-V relations of K-Shaw2 (black) and K-Shaw2 T330G (red) in the absence (open) and presence of 1 mM sevoflurane (filled). Solid lines are
the best-fits to the Boltzmann equation. Best-fit parameters are summarized in Fig 2 and Table A in S1 File. (C) The voltage dependence of the conductance
ratio (GSevo/G0) K-Shaw2 (black) and K-Shaw2 T330G (red).
doi:10.1371/journal.pone.0143363.g008
Fig 9. Positive modulation by sevoflurane is T1 domain-independent in Kv1.2 and Kv1.2-FRAKT, and T1 domain-dependent in K-Shaw2. (A)
Concentration-response relations of various general anesthetics acting on ΔT1-Kv1.2. Solid line is the best fit to the Hill equation for n-butanol. (B)
Concentration-response relations of various general anesthetics acting on ΔT1-Kv1.2 FRAKT. Solid lines are the best fits to the Hill equation (propofol and n-
butanol) or double Hill equation (sevoflurane, isoflurane, and halothane). Best-fit parameters for results in panels A and B are summarized in Table 1. (C)
Concentration-response relations of sevoflurane acting on K-Shaw2 and ΔT1-K-Shaw2. Solid line is the best-fit double Hill equation to the K-Shaw2 data with
the following parameters: K1 = 0.08 mM, A1 = 0.18, nH1 = 1, K2 = 4 mM, A2 = 1.4, nH2 = 1. These parameters are similar to those previously published for wild
type K-Shaw2 (Table 1) [7]. K-Shaw2 and ΔT1-K-Shaw2 were tested at +60 mV. N = 2–8 oocytes for each dose.
doi:10.1371/journal.pone.0143363.g009
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also independent of the T1 domain; 5) the reverse K-Shaw2-T330G mutation at a position
equivalent to that of G329 in Kv1.2 nearly eliminates the sevoflurane-induced leftward shift of
the K-Shaw2 G-V relation. These results suggest that G329 in the S4-S5 linker plays a key role
controlling the potentiation of the Kv1.2 current by sevoflurane. In the light of these observa-
tions, we explored putative sites of sevoflurane action in the Kv1.2 channel to help elucidate a
working mechanism of anesthetic action. To identify putative sevoflurane binding sites with
atomic resolution, we applied docking and MD-based free-energy calculations. Specifically,
we docked sevoflurane against an ensemble of 120 membrane-equilibrated structures of
ΔT1-Kv1.2 and ΔT1-Kv1.2-G329T in the activated-open and resting-closed conformations
(Materials and Methods and S1 File). The sampling of an ensemble accounts for the molecular
flexibility of the protein. Then, starting from sevoflurane-bound channel structures, we carried
out free-energy calculations using the LIE method to resolve site-specific affinities of sevoflur-
ane (S1 File). This calculation assumes that individual sites are independent. Also, because
electrophysiological experiments do not measure actual binding of the anesthetics to the Kv
channels, we made no attempt to quantitatively compare an “apparent” affinity (electrophysio-
logical estimate) against the calculated affinities of multiple putative sites (LIE estimates). To
learn about relative properties of putative sites, we only compared calculated affinities between
different classes of sites in putative resting-closed and activated-open conformations.
Sevoflurane is found at four distinct locations on the Kv channel structures, hereafter called
sites 1–4 (Fig 10A). Sites 1 and 2 are located near the S4-S5 linker at the internal face of the
channel; site 3 is formed in the S5-S6 interface of adjacent subunits; and site 4 involves discrete
pockets around the selectivity filter at the extracellular face of the channel. Sites 1 and 2 are
near G329T in the mutant channel (Fig 10B). Despite a similar pattern of binding sites in
Kv1.2 and Kv1.2-G329T, the LIE analysis of interaction energies revealed subsets of non-over-
lapping sites with relatively low and high affinities (Fig 10C; Table B in S1 File). Sites 1–3
involving the S4-S5 linker and pore domain exhibit relatively low-affinities with binding con-
stants ranging between 0.01–0.2 mM-1; and site 4 around the selectivity filter exhibits relatively
high-affinity ranging between 0.3–0.4 mM-1. In addition, the binding constants of sites 1 and 3
Fig 10. Putative sevoflurane binding sites in the Kv1.2 channel. (A) Representation of four distinct
sevoflurane binding locations on Kv1.2: site 1 (light blue), 2 (blue), 3 (black) and 4 (purple). Each pair of
subunits is represented in green and orange. Mutation G329T is highlighted yellow. (B) Close-up view of
ligand binding sites and mutation. Note that site 2 is in close proximity to the mutated residue G329T. (C)
Binding constants of individual sevoflurane sites. These estimates were obtained using the LIE method as
described under S1 File. O and C stand for activation-open and resting-closed conformations of the channel.
doi:10.1371/journal.pone.0143363.g010
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display modest conformation dependence, with a slight preference for the open state in
Kv1.2-G329T. In contrast, the site 2 binding constants in the resting-closed conformation
are ~7-fold greater than in the fully open conformation, for both wild type Kv1.2 and
Kv1.2-G329T. Site 4 exhibits the largest binding constants, but no conformation dependence
(Fig 10C; Table B in S1 File). These results are consistent with a scenario in which the modula-
tion of Kv1.2 channels by sevoflurane results from multiple interactions with distinct classes of
sites. A subset of these sites is possibly responsible for leftward shifting the G-V relation and
another potentially contributing to the net increase in Gmax. However, since the calculated
binding constants of wild type Kv1.2 and Kv1.2-G329T are generally similar (ranging between
0.02–0.4 mM-1), additional factors probably determine the larger efficacy of sevoflurane acting
on the mutant channel.
Discussion
Distinct gating processes in Kv channels
Shaker-related Kv1 channels undergo complex and strongly voltage-dependent activation gat-
ing involving sequential transitions between multiple closed states and a final cooperative
opening step [29–31]. This mechanism has two major steps. The first corresponds to a major
conformational change of the voltage sensors, which unlocks the gating machinery; and the
second corresponds to a final cooperative rearrangement of the voltage sensors, which ulti-
mately opens the intracellular activation gate [32, 33]. Whereas the first step is associated with
movement of a large gating charge (14–16 e0), the second only involves movement of a small
gating charge (~1 e0). Therefore, tightly coupled voltage-dependent gating is typically domi-
nated by the first component. The previously investigated Shaker-ILT voltage sensor mutant
clearly unveiled the second step by greatly shifting its voltage dependence toward depolarized
voltages [32, 33]. The K-Shaw2 channel is a special case where the weakly voltage-dependent
component is sufficient to control activation gating and can be described as a simple first-order
equilibrium [34, 35]. Here, we showed that mutations that converted the S4-S5 linker of Kv1.2
into that of K-Shaw2 exhibit a Shaker-ILT-like gating phenotype, albeit the separation of the
two activation components is further exaggerated. These mutations do not have much effect on
the first sharp component of the G-V relation (Table A in S1 File). In contrast, the second gat-
ing component of the mutant G-V relations becomes clearly evident as a result of a robust
depolarizing shift of its voltage dependence. Remarkably, the profile and voltage dependence of
this depolarized component resembles the K-Shaw2 G-V relation. We propose that the G329T
mutation at the C-terminal end of the S4-S5 linker induces these changes by greatly reducing
the weakly voltage-dependent equilibrium constant of the cooperative opening transition. Such
a reduction could directly result from hampering protein backbone flexibility caused by the
glycine to threonine substitution at a critical position. The flexibility conferred by glycine at
this position might create a critical pivot point generally conserved in a majority of Kv channels
(Fig C in S1 File). The rare natural substitution of glycine for threonine at the equivalent posi-
tion in wild type K-Shaw2 might help determine the unusual gating properties of K-Shaw2 and
its distinctive strong positive modulation by sevoflurane [7].
Putative mechanism of sevoflurane action on Kv channels
The positive modulation of Kv channels by sevoflurane is associated with two separable effects.
One shifts the G-V relation leftward and the other increases the Gmax. Sevoflurane might thus
simultaneously influence two separable processes by acting at two distinct sites. We propose
that sevoflurane shifts the G-V relation leftward by having a positive influence on the final
weakly voltage-dependent component of gating that ultimately controls the opening of the Kv
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channel. The anesthetic might achieve this by interacting with the S4-S5 linker and the pore
domain. The Kv channel’s S4 voltage sensor transmits its final concerted conformational
change to the S4-S5 linker, which in turn acts on the intracellular activation gate to open it [14,
15, 18]. This idea helps explain quantitatively distinct sevoflurane modulations of Kv1.2 and
K-Shaw2 channels and how S4-S5 linker mutations have profound effects on the final gating
component and the positive modulation by sevoflurane and other general anesthetics.
K-Shaw2 gating is dominated by the concerted conformational change transmitted by the
S4-S5 linker, (in contrast to more conventional gating in Kv1 channels; see section above), and
sevoflurane might selectively influence this process. Therefore, sevoflurane appears to have a
greater effect on the voltage dependence of K-Shaw2 than on that of Kv1.2. However, upon
introducing the G329T mutation at the C-terminal end of the Kv1.2 S4-S5 linker, the final gat-
ing component appears rightward shifted and magnified. Consequently, the potentiation of the
Kv1.2-G329T by sevoflurane is also magnified, which seems to namely result from selectively
leftward shifting the final gating component. To cause this shift, sevoflurane might increase the
equilibrium constant of the opening step by destabilizing the pre-open closed state, as previ-
ously proposed for the wild-type K-Shaw2 [6] (see below). Supporting these ideas further, the
reverse K-Shaw2 T330G mutation conversely eliminates the sevoflurane-induced leftward shift
of the G-V relation, albeit has no significant effect on voltage-dependent gating (Fig 8). Addi-
tionally, this experiment surprisingly revealed that T330 is only a critical determinant of the
sevoflurane effect on voltage dependence because the T330G mutation did not significantly
affect the sevoflurane-induced increase in Gmax. This selectivity strongly suggests that another
site is independently responsible for the sevoflurane-induced increase in the Gmax. Given the
quick onset and reversibility of the positive modulation [7], we propose that, rather that
increasing the number of functional channels, sevoflurane probably increases the maximum
open probability and/or the unitary conductance. The potentiation of the ShakerB Kv channel
by isoflurane results from the combination of both effects [36]. Further work is needed to
investigate the biophysical and molecular underpinnings of the sevoflurane-induced increase
in Gmax.
Exploring putative sevoflurane binding sites and mechanisms of action
in the Kv1.2 channel
We gained more specific insights into sites and mechanisms of sevoflurane action from atomic
level simulations of a membrane-equilibrated Kv1.2 model in the resting closed and open
states. In silico docking of sevoflurane to these conformations, along with free-energy calcula-
tions, revealed putative sites with distinct binding affinities in regions experimentally impli-
cated in anesthetic action by the comparative study of the Kv1.2 and K-Shaw2 channels. Sites 1
and 2 are in close proximity to the S4-S5 linker. Sevoflurane binding to site 2 in Kv1.2 and
Kv1.2-G329T is, however, significantly weaker in the open state than in the resting closed state
(~7-fold). Thus, a simple stabilization of the open state alone does not explain the sevoflurane-
induced leftward shift in the G-V relation. Rather, this shift might result from the crosstalk
among various interacting sites, which globally destabilizes the pre-open closed state. Further
modeling of sevoflurane binding sites in the pre-open closed state will be necessary to examine
this possibility.
Why does Kv1.2-G329T exhibit greater sevoflurane-induced potentiation than the wild type
counterpart? The G329T mutation alone might stabilize the pre-open closed state and conse-
quently the voltage dependence of the opening step is better resolved as a separate depolarized
gating component of the G-V relation (see above). That is, actual opening of the channel
becomes harder. If sevoflurane binds to a pre-open closed state displaying an increased
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presence in the G329T mutant, it might have greater influence on its stability. Presumably,
binding of sevoflurane to interacting sites in the tetrameric Kv1.2-G329T opposes the negative
effect of the mutation by destabilizing the pre-open closed state, which results in the observed
sevoflurane-induced leftward shift of the G-V relation’s second gating component. Essentially,
sevoflurane might act similarly on wild type Kv1.2. In this case, however, the tight coupling
between voltage-dependent activation and channel opening blurs the separation of the gating
components in the G-V relation. This implies that, relative to the G329T, the relative availabil-
ity of binding sites in the pre-open closed state of wild type Kv1.2 is more limited. Therefore,
the dynamic range for positive modulation of wild type Kv1.2 by sevoflurane is more restricted
and the potentiation less efficacious.
Sharply in contrast to sites 1–3, site 4 located externally around the selectivity filter displays
the strongest binding constants (on average, ~5-fold stronger than the highest affinity of site
2), but little state dependence. Binding of sevoflurane to this site is particularly interesting
because it might affect the stability of the selectivity filter, which plays a role in a mechanism of
Kv channel inactivation [37]. Stabilization of the open conducting conformation of the selectiv-
ity filter following sevoflurane binding to site 4 could help explain the sevoflurane-induced
increase in the Gmax. Further experimental validation would, however, be necessary to test
this hypothesis. Multiple binding sites with distinct binding constants is consistent with the
presence of low- and high-affinity components of the Kv1.2-FRAKT and Kv1.2-G329T con-
centration-potentiation relations for various inhaled anesthetics (Figs 4 and 5). However, no
quantitative relationships could be made at this time.
Surprisingly, the positive modulation of K-Shaw2 by sevoflurane is T1 domain-dependent,
whereas that of Kv1.2-FRAKT is not. This observation suggests that other interactions contrib-
ute to the ability of sevoflurane to influence the final opening step. Supporting this idea, the T1
domain scaffolding of Kv1.2 and K-Shaw2 channels exhibit significant differences in regions
that have been implicated in gating [28, 38].
Concluding remarks
Three major mechanistic conclusions emerge from this study. First, the positive modulation of
Kv1.2 channels by general anesthetics depends on a single S4-S5 linker residue (G329). G329T
confers dramatic positive modulation by sevoflurane Threonine is the residue naturally found
at the equivalent position in the K-Shaw2 (T330), a Kv channel that normally exhibits strong
positive modulation by sevoflurane. Underscoring the critical role of T330, the converse muta-
tion T330G abolished voltage-dependent potentiation of K-Shaw2 by sevoflurane without
affecting the sevoflurane-induced increase in Gmax. Such a differential effect suggests separable
sites of sevoflurane action, which is consistent with modeling results. The location of G329 and
T330 in the S4-S5 linker of these Kv channels suggests that this position is a critical pivot point
of voltage-dependent gating. Second, depending on Kv channel specific interactions, the cyto-
plasmic T1 domain may additionally contribute to the positive modulation of K-Shaw2 by
sevoflurane. Third, molecular modeling suggests that positive modulation results from alloste-
ric interactions between sites 1–3, the pore domain and the S4-S5 linker -a critical moving part
involved in activation gating. These interactions might favorably influence pore opening. Addi-
tionally, binding to site 4 might stabilize the open state. These mechanisms serve as framework
to explain how Kv1 channels might play a role in general anesthetic action.
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